Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Phase 2 Not yet recruiting 30 enrolled BeBetter Med Inc

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as first-line treatment for locally advanced, recurrent, or metastatic non-small cell lung cancer carrying EGFR exon 20 insertion mutations.

Timeline

Start: 2024-07
Primary completion: 2027-06
Completion: 2027-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BEBT-109	Unknown	120 mg	Oral
Subject	BEBT-109	Unknown	180 mg	Oral
Background	Carboplatin	Small molecule	—	Intravenous
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Summary

Timeline

Drugs

Indications